glimepiride has been researched along with canagliflozin in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (73.33) | 24.3611 |
| 2020's | 4 (26.67) | 2.80 |
| Authors | Studies |
|---|---|
| Arias, P; Balis, DA; Canovatchel, W; Cefalu, WT; Leiter, LA; Meininger, G; Niskanen, L; Xie, J; Yoon, KH | 1 |
| Diamant, M; Morsink, LM | 1 |
| Seufert, J | 1 |
| Arias, P; Balis, DA; Canovatchel, W; Langslet, G; Leiter, LA; Meininger, G; Millington, D; Vercruysse, F; Xie, J; Yoon, KH | 1 |
| Alba, M; Cerdas, S; Chacon, Mdel P; Eliaschewitz, FG; Lavalle-González, FJ; Tong, C | 1 |
| Blonde, L; Canovatchel, W; Fung, A; Meininger, G; Stenlöf, K; Xie, J | 1 |
| Ako, J; Anzai, T; Eguchi, K; Inoue, T; Kitakaze, M; Murohara, T; Node, K; Oyama, J; Saito, Y; Sakata, Y; Sata, M; Sato, Y; Shimizu, W; Suzuki, M; Taguchi, I; Tanaka, A; Tomiyama, H; Ueda, S; Uematsu, M; Watada, H; Yamashina, A | 1 |
| Bailey, RA; Blonde, L; Meininger, G; Patel, CA; Vijapurkar, U | 1 |
| Balis, D; Canovatchel, W; Desai, M; Rosenthal, N; Sun, D; Xie, J; Yavin, Y | 1 |
| Algeelani, S; Alkhelb, D; Greenblatt, DJ | 1 |
| Cuddihy, R; Davies, MJ; Garvey, WT; Leiter, LA; List, J; Ren, J; Van Gaal, L; Vijapurkar, U | 1 |
| Imai, T; Matsunaga, K; Minamino, T; Nakamura, I; Node, K; Ozaki, Y; Sata, M; Shimabukuro, M; Tanaka, A | 1 |
| Ajioka, M; Hiramitsu, S; Imai, T; Kadokami, T; Node, K; Shimabukuro, M; Suzuki, M; Takahashi, N; Tanaka, A; Yamaguchi, S | 1 |
| Eguchi, K; Kitada, S; Kodama, K; Node, K; Ohte, N; Seo, Y; Takeishi, Y; Tanaka, A; Teragawa, H; Yamada, T | 1 |
| Dohi, T; Hikoso, S; Nakatani, D; Nanasato, M; Node, K; Sakata, Y; Shimizu, W; Tanaka, A | 1 |
1 review(s) available for glimepiride and canagliflozin
| Article | Year |
|---|---|
[Oral add-on therapy to metformin in type 2 diabetes mellitus: a direct comparison beween canagliflozin and glimepiride].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Endpoint Determination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Male; Metformin; Middle Aged; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Thiophenes | 2014 |
8 trial(s) available for glimepiride and canagliflozin
| Article | Year |
|---|---|
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiophenes; Treatment Outcome; Young Adult | 2013 |
Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study.
Topics: Blood Glucose; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Thiophenes; Time Factors; Treatment Outcome; Weight Loss | 2015 |
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Latin America; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome | 2016 |
Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Canagliflozin; Chronic Disease; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Quality of Life; Sulfonylurea Compounds | 2016 |
Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes.
Topics: Adiponectin; Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inflammation; Leptin; Male; Metformin; Middle Aged; Molybdoferredoxin; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Treatment Outcome; Tumor Necrosis Factor-alpha | 2018 |
Effect of canagliflozin on white blood cell counts in patients with type 2 diabetes and heart failure: A subanalysis of the randomized CANDLE trial.
Topics: Aged; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents; Leukocyte Count; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Treatment Outcome; Ventricular Function, Left | 2022 |
Influence of left ventricular ejection fraction on the reduction in N-terminal pro-brain natriuretic peptide by canagliflozin in patients with heart failure and type 2 diabetes: A sub analysis of the CANDLE trial.
Topics: Biomarkers; Canagliflozin; Diabetes Mellitus, Type 2; Heart Failure; Humans; Natriuretic Peptide, Brain; Peptide Fragments; Stroke Volume; Ventricular Function, Left | 2023 |
Relationship Between Canagliflozin, Sodium Glucose Cotransporter 2 Inhibitor, and Hematopoietic Effects in Patients With Diabetes and Mild Heart Failure: Results From the CANDLE Trial.
Topics: Canagliflozin; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Heart Failure; Humans; Hypoglycemic Agents; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors | 2023 |
6 other study(ies) available for glimepiride and canagliflozin
| Article | Year |
|---|---|
SGLT2 inhibitors for diabetes: turning symptoms into therapy.
Topics: Canagliflozin; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiophenes | 2013 |
Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks.
Topics: Adiposity; Aged; Body Composition; Body Mass Index; Body Weight; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Time Factors; Waist Circumference; Weight Loss | 2016 |
A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures.
Topics: Aged; Blood Glucose; Blood Pressure Determination; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Quality Indicators, Health Care; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Thiophenes; Treatment Outcome | 2016 |
Renal safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus.
Topics: Adult; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Humans; Hypoglycemic Agents; Incidence; Kidney; Kidney Diseases; Male; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Time Factors | 2017 |
Inhibitory effects of sulfonylureas and non-steroidal anti-inflammatory drugs on in vitro metabolism of canagliflozin in human liver microsomes.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Canagliflozin; Chlorpropamide; Diclofenac; Dose-Response Relationship, Drug; Drug Interactions; Gliclazide; Humans; Hypoglycemic Agents; Microsomes, Liver; Niflumic Acid; Sulfonylurea Compounds | 2018 |
Canagliflozin reduces proteinuria by targeting hyperinsulinaemia in diabetes patients with heart failure: A post hoc analysis of the CANDLE trial.
Topics: Canagliflozin; Chronic Disease; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulins; Proteinuria; Sodium-Glucose Transporter 2 Inhibitors | 2023 |